Bringing science and development together through news and analysis

Substandard drugs pile on Nigeria’s malaria burden
  • Substandard drugs pile on Nigeria’s malaria burden

Copyright: Flickr/PAHO/WHO

Speed read

  • More than 48 million in Nigeria get malaria a year, resulting in 180,000 deaths

  • About 9.2 per cent of antimalarials bought in a Nigerian city are of poor quality

  • An expert says fake antimalarials could increase antibiotics use and resistance

Shares
[LAGOS] Efforts to curb the serious malaria problem in Nigeria could become more challenging due to the rampant use of sub-standard medicines, a new study suggests.

The study conducted in Enugu metropolis, south-east Nigeria, by researchers from University of Nigeria and UK-based London School of Hygiene and Tropical Medicine (LSHTM), found 9.2 per cent of 3,024 of antimalarias as being of poor standard.

Researchers say patients risk not receiving the correct treatment dose, potentially contributing to the development of resistance to the main drug used to treat malaria.

“Our study highlights the need for increased pharmacovigilance and greater regulatory control on local ACT production, importation, drug storage and provision.”

Obinna Onwujekwe, University of Nigeria


According to a statement from the LSHTM, malaria attacks 48 million people in Nigeria a year, resulting in 180,000 deaths, thus making the country bear the brunt of the disease more than any other in the world.  

In 2013, the researchers bought antimalarials in Enugu, a city with about 3.3 million people, from 421 outlets such as pharmacies and public health facilities by using mystery clients who pretended to be sick of malaria or whotold vendors that they would be assessing the quality of the medicines, says the study published in PLOS One on 27 May.

Harparkash Kaur, the study’s lead author and drug quality expert at LSHTM, tellsSciDev.Net that artemisinin combination therapy (ACT) is the first line drug endorsed by the WHO to treat malaria, and that there is no independent information on the quality of these drugs in Nigeria.

 “The study sample area is small as Nigeria is a big country with regulations controlled at state level, but our study findings from Enugu can be completely generalised to southeast and south-south Nigeria — home to more than 60 million people,” Kaur adds.

The researchers classified the medicines “as acceptable quality, falsified (fake drugs which do not contain the stated active pharmaceutical ingredient or API), sub-standard (which contain inadequate amounts of the active ingredients), or degraded,” according to the LSHTM statement.

The studyshows after analysing the antimalarials 9.2 per cent of them were of poor quality, 1.2 per centwere falsified, 1.3 per cent were degraded, and 6.8 per centwere substandard in one or more of the APIs.

Study co-author Obinna Onwujekwe, a professor of medicine at the University of Nigeria, Enugu campus, says: “Our study highlights the need for increased pharmacovigilance and greater regulatory control on local ACT production, importation, drug storage and provision. The manufacturers of fake drugs need to be found and shut down. The manufacturers of substandard drugs need their factory processes strengthened to produce quality assured drugs.”
Bernard Akpa, a pharmacist based in Makurdi, north-central Nigeria, said the finding could be the result of the absence of a certified channel for bringing drugs into pharmacies in Nigeria.

Rotimi Akereye, a general medical practitioner with the Bingham University Teaching Hospital in Nigeria, adds that the development could be responsible for the increasing resistance to antimalarials noticed among Nigerians.

“Prescribed drugs are in most cases not working and this has led to the abuse of antibiotics which are being introduced, thinking that the illness is no longer malaria but other types of fever,” Akerele says.
 
This article has been produced by SciDev.Net's sub-Saharan Africa desk.

References

Harparkash Kaur and others, Quality of artemisinin-based combination formulations for malaria treatment: prevalence and risk factors for poor quality medicines in public facilities and private sector drug outlets in Enugu, Nigeria (PLOS One, 27 May 2015)
Republish
We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.